Nocodazole
Identification
- Name
- Nocodazole
- Accession Number
- DB08313
- Description
Nocodazole is an antineoplastic agent which exerts its effect by depolymerizing microtubules.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 301.32
Monoisotopic: 301.052111923 - Chemical Formula
- C14H11N3O3S
- Synonyms
- Nocodazol
- Nocodazole
- Nocodazolum
- Oncodazole
- External IDs
- R 17,934
- R 17934
- R-17934
Pharmacology
- Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset
- Indication
- Not Available
- Contraindications & Blackbox Warnings
- Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
- Pharmacodynamics
- Not Available
- Mechanism of action
Target Actions Organism UHematopoietic prostaglandin D synthase Not Available Humans - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
- Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareDarbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nocodazole. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Nocodazole. Methotrexate The excretion of Methotrexate can be decreased when combined with Nocodazole. Methoxy polyethylene glycol-epoetin beta The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Nocodazole. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Nocodazole. Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzimidazoles
- Sub Class
- Not Available
- Direct Parent
- Benzimidazoles
- Alternative Parents
- Thiophene carboxylic acids and derivatives / Aryl ketones / Benzenoids / Imidazoles / Heteroaromatic compounds / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds show 2 more
- Substituents
- Aromatic heteropolycyclic compound / Aryl ketone / Azacycle / Azole / Benzenoid / Benzimidazole / Carboximidic acid derivative / Heteroaromatic compound / Hydrocarbon derivative / Imidazole show 11 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- carbamate ester, thiophenes, aromatic ketone, benzimidazoles (CHEBI:34892)
Chemical Identifiers
- UNII
- SH1WY3R615
- CAS number
- 31430-18-9
- InChI Key
- KYRVNWMVYQXFEU-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H11N3O3S/c1-20-14(19)17-13-15-9-5-4-8(7-10(9)16-13)12(18)11-3-2-6-21-11/h2-7H,1H3,(H2,15,16,17,19)
- IUPAC Name
- methyl N-[5-(thiophene-2-carbonyl)-1H-1,3-benzodiazol-2-yl]carbamate
- SMILES
- COC(=O)NC1=NC2=CC(=CC=C2N1)C(=O)C1=CC=CS1
References
- General References
- Not Available
- External Links
- KEGG Drug
- D05197
- KEGG Compound
- C13719
- PubChem Compound
- 4122
- PubChem Substance
- 99444784
- ChemSpider
- 3979
- BindingDB
- 97233
- ChEBI
- 34892
- ChEMBL
- CHEMBL9514
- ZINC
- ZINC000000056509
- PDBe Ligand
- NZO
- Wikipedia
- Nocodazole
- PDB Entries
- 3ee2 / 5ca1
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0184 mg/mL ALOGPS logP 2.83 ALOGPS logP 3.17 ChemAxon logS -4.2 ALOGPS pKa (Strongest Acidic) 9.11 ChemAxon pKa (Strongest Basic) 3.34 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 84.08 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 78.39 m3·mol-1 ChemAxon Polarizability 30.67 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9907 Blood Brain Barrier + 0.8782 Caco-2 permeable + 0.6164 P-glycoprotein substrate Non-substrate 0.6441 P-glycoprotein inhibitor I Non-inhibitor 0.6223 P-glycoprotein inhibitor II Non-inhibitor 0.622 Renal organic cation transporter Non-inhibitor 0.9022 CYP450 2C9 substrate Non-substrate 0.7228 CYP450 2D6 substrate Non-substrate 0.8394 CYP450 3A4 substrate Non-substrate 0.7098 CYP450 1A2 substrate Inhibitor 0.9108 CYP450 2C9 inhibitor Non-inhibitor 0.9072 CYP450 2D6 inhibitor Non-inhibitor 0.9449 CYP450 2C19 inhibitor Non-inhibitor 0.9025 CYP450 3A4 inhibitor Non-inhibitor 0.931 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8681 Ames test Non AMES toxic 0.5877 Carcinogenicity Non-carcinogens 0.9155 Biodegradation Not ready biodegradable 0.9841 Rat acute toxicity 2.3190 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.981 hERG inhibition (predictor II) Non-inhibitor 0.8761
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-00di-3790000000-449c2492c2ab67a70502
Targets

Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Accelerate your drug discovery research with our ADMET & drug target dataset
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Protein homodimerization activity
- Specific Function
- Bifunctional enzyme which catalyzes both the conversion of PGH2 to PGD2, a prostaglandin involved in smooth muscle contraction/relaxation and a potent inhibitor of platelet aggregation, and the con...
- Gene Name
- HPGDS
- Uniprot ID
- O60760
- Uniprot Name
- Hematopoietic prostaglandin D synthase
- Molecular Weight
- 23343.65 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Drug created on September 15, 2010 21:30 / Updated on February 21, 2021 18:52